Kamada Of Israel Gets U.S. FDA Orphan Drug Status For Diabetes
This article was originally published in PharmAsia News
Executive Summary
Israel's Kamada received U.S. FDA clearance for its orphan drug application for D1-AAT treatment for juvenile diabetes